<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1238">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377646</url>
  </required_header>
  <id_info>
    <org_study_id>UR17DN02-001</org_study_id>
    <secondary_id>TN2020-NAT-INS-38</secondary_id>
    <nct_id>NCT04377646</nct_id>
  </id_info>
  <brief_title>A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers</brief_title>
  <acronym>COVID-Milit</acronym>
  <official_title>A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Military Hospital of Tunis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UR17DN02 : Autoimmune Diseases Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dacima Consulting</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Military Hospital of Tunis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter randomized clinical trial aiming to assess the efficacy of hydroxychloroquine
      associated to Zinc compared to hydroxychloroquine, in the prevention of Military Health
      Professionals Exposed to SARS CoV2 in Tunisia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description: The study is a multicenter randomized controlled double blind clinical
      trial, including up to 660 military health professionals working in Tunisia and exposed to
      SARS CoV2 at different levels (2 levels of exposure).

      The trial will assess the efficacy of hydroxychloroquine associated to Zinc compared to
      hydrxyochloroquine. Randomization will be performed by IWRS (Interactive Web Response System)
      by random double blocs of 9 and 6.

      Collected data are managed by the electronic data capture system (DACIMA Clinical
      Suite),according to the FDA 21 CFR part 11 requirements (Food and Drug Administration 21 Code
      of Federal Regulations part 11), the EU GDPR (European General Data Protection Regulation),
      the HIPAA specifications (Health Insurance Portability and Accountability Act), and the ICH
      standards (International Conference on Harmonisation)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 4, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 24, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind randomized clinical trial with 3 arms</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Random blind allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>SARS CoV2 infection</measure>
    <time_frame>At 2 months of follow-up</time_frame>
    <description>Frequency of confirmed SARS CoV2 infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COVID-19 symptoms description</measure>
    <time_frame>At 2 months of follow-up</time_frame>
    <description>Any COVID-19 related symptoms (cough, fever, headache, vomiting, nausea, dyspnea, diarrhea, smell disorder,conjunctivitis, dizziness)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>each month up to 2 months</time_frame>
    <description>Any adverse event or serious adverse event</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Sars-CoV2</condition>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine &amp; Zinc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive:
Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.
Zinc 15 mg at daily dose up to 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive:
Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.
Placebo of Zinc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will receive a double placebo (Hydroxychloroquine and Zinc) up to 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>400 mg at day 1 and day 2, then 400 mg weekly up to 2 months</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_label>Hydroxychloroquine &amp; Zinc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine (placebo)</intervention_name>
    <description>1 pill at day 1 and day 2, then 1 pill weekly up to 2 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>15 mg per day up to 2 months</description>
    <arm_group_label>Hydroxychloroquine &amp; Zinc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc (Placebo)</intervention_name>
    <description>1 pill per day up to 2 months</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No self-medication with chloroquine, hydroxychloroquine or antivirals

          -  COVID-19 negative diagnosis confirmed by &quot;rapid test&quot; and &quot;PCR test&quot; (Polymerase Chain
             Reaction test)

          -  No clinical symptoms suggestive of COVID-19

          -  Having given written consent for their participation in the study

        Exclusion Criteria:

          -  Participation in other clinical trials for the treatment or prevention of SARS-COV-2
             infection within 30 days before inclusion

          -  Hypersensitivity to any of the drugs or to any of its excipients.

          -  ECG showing rhythm disturbances, QT interval&gt; 500 ms, conduction disturbances.

          -  Severe hepatic impairment.

          -  Concomitant treatments : colchicin, ergot of rye, pimozide, mizolastin, simvastatin,
             lomitapide, alfuzosin, dapoxetin, avanafil, ivabradin, eplerenone, dronedaron,
             quetiapine, ticagrelor, cisapride, astemizole, astemizol.

          -  Retinal pathology.

          -  Epilepsy.

          -  Myasthenia.

          -  Psoriasis.

          -  Methemoglobinemia.

          -  Porphyria.

          -  Pregnant or lactating women

          -  Contraindication to the study products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faida Ajili, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Military Hospital of Tunis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nejla Mrabet, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Military Hospital of Tunis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faida Ajili, MD</last_name>
    <phone>+21698631188</phone>
    <email>faida1977@yahoo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neja Stambouli, PhD</last_name>
    <phone>+21655104234</phone>
    <email>nejlastam@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Military Hospital of Tunis</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <contact>
      <last_name>Faida Ajili, MD</last_name>
      <phone>+21698631188</phone>
      <email>faida1977@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nejla Stambouli, PhD</last_name>
      <phone>+21655104234</phone>
      <email>nejlastam@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylaxis</keyword>
  <keyword>Zinc</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <keyword>Health Professionals</keyword>
  <keyword>Military</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

